- Home
- / Insulet
Insulet
Stock Price
$232.4
2024-10-29
Market Capitalization
$16.3 B
2024-10-29
Revenue
$2.1 B
FY, 2024
Insulet Summary
Company Summary
- Overview
- Insulet is a medical device company that develops a tubeless insulin delivery system. It offers an Omnipod insulin management system integrated with a continuous glucose monitor to manage blood sugar.
- Type
- Public
- Status
- Active
- Founded
- 2000
- HQ
- Acton, MA, US | view all locations
- Website
- https://www.insulet.com
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Jim Hollingshead, Director, President and Chief Executive Officer
Luciana Borio, Director
Deborah Gordon, Vice President, Investor Relations
Operating MetricsView all
Patents Pending
32
FY, 2016
Patents Issued
23
FY, 2016
Trademarks
11
FY, 2022
LocationsView all
13 locations detected
Acton, MA HQ
United States
100 Nagog Park
Irvine, CA
United States
1562 Reynolds Ave
San Diego, CA
United States
9276 Scranton Road, 4th Floor
Sydney, NSW
Australia
Level 16, Tower 2, Darling Park, 201 Sussex Street
Wien, Wien
Austria
Parkring 2
Oakville, ON
Canada
1540 Cornwall Road, Suite 201
Insulet Financials
Summary Financials
- Revenue (FY, 2024)
- $2.1B
- Gross profit (FY, 2024)
- $1.4B
- Net income (FY, 2024)
- $418.3M
- Cash (FY, 2024)
- $953.4M
- EBIT (FY, 2024)
- $308.9M
- Enterprise value
- $16.7B